Accreditation and Credit Statements
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the Radiological Society of North America (RSNA) and the Association of University Radiologists (AUR). The RSNA is accredited by the ACCME to provide continuing medical education for physicians.
This activity has been approved for AMA PRA Category 1 CreditTM.
Radiologists, researchers, or other allied health professionals, trainees, and administrators in academic radiology.
AUR CME Activity Disclosure
Disclosure Refusal Statement
Further, the provider must be able to show that individuals in a position to control the content of an education activity, including committee members, reviewers, planners, authors, and presenters, has disclosed all financial relationships with ineligible companies to the provider. Individuals in a position to control the content must disclose regardless of their view of the relevance of the relationship to the education. The provider must identify, mitigate, and disclose all identified financial relationships to an education activity being delivered to the learners.
If you have or have had within the previous 24 months such a relationship or affiliation, you must disclose this information. Likewise, disclosure that no relationship(s) exists is also required. The intent of this policy is not to prevent an individual with a financial relationship from participating; however, in accordance with ACCME standards, the AUR has developed policies and procedures to manage identified financial relationships.
This indicates discussion of uses not approved by the FDA. The RSNA and AUR recognize that at educational meetings, faculty may discuss the application of some devices, materials, or pharmaceuticals that are not FDA approved. In keeping with the highest standards of professional integrity and ethics, RSNA and AUR require that faculty fully disclose to their audience that there will be discussion of the unlabeled use of a commercial product, device, or pharmaceutical that has not been approved for such purpose by the FDA.